ZeOmega Launches Integrated Medication Management Solution to Improve Patient Safety and Lower Medical Costs

PLANO, Texas – April 8, 2015 – ZeOmega Inc., a market leader in population health solutions, today launched Jiva Integrated Medication Management, which gives providers and health plans the embedded intelligence and workflow needed to integrate medication management into the overall care management process. This will help healthcare organizations more effectively identify patients who could benefit from medication, case, or disease management, particularly those impacted by chronic diseases such as hypertension, coronary heart disease, stroke, diabetes, cancer, and other pulmonary issues.

Today, more than 80 percent of the annual U.S. healthcare spend goes to treat chronic diseases, totaling more than $160 billion; and, according to the World Health Organization (WHO), 157 million Americans will have one or more chronic diseases by 2020. Managing the care of these chronically ill patients is further complicated by the fact they typically see two primary care physicians and five specialists annually. For those chronic conditions that cannot be treated with diet and lifestyle changes, medications are the most common treatment option, yet patients often fail to meet therapeutic goals due to medication-related issues.

Medication-related events continue to negatively impact healthcare, including nearly 700,000 emergency department visits and 2 million hospitalizations each year in the U.S. that are due to preventable adverse drug events.

“The industry is converging on the idea that driving down healthcare costs while improving quality of care is possible only by approaching patient care management holistically. Healthcare organizations that recognize this are looking for ways to break the traditional silos between their care management and pharmacy management programs whether those programs are handled by a Pharmacy Benefit Manager or an in-house pharmacy group,” said Nandini Rangaswamy, ZeOmega’s executive vice president and chief strategy officer. “Jiva’s Integrated Medication Management solves that problem by seamlessly integrating care and pharmacy management programs, enabling teams to work collaboratively on a patient’s needs – whether it is better communication or coordination of medication-related services – thus driving healthier patient outcomes while lowering overall costs.”

Medication, when used as prescribed, serves as a powerful source of prevention and management of many chronic conditions. However, issues such as non-adherence, improper dosing, contraindications, missed therapies, and duplicate therapies, among others, can adversely impact the patient in a matter of months, weeks, or even days, resulting in more hospitalizations and emergency department visits. Jiva Integrated Medication Management reduces these events and associated costs by delivering patient-centric information, analytics, workflow, and communication all on one platform, helping providers close potential gaps in medication management care.

The Jiva Integrated Medication Management platform also maximizes government program compliance and scores by being CMS compliant in the Medicare Part D solution, and encompasses embedded intelligence and workflow to help healthcare organizations proactively meet medication-related Star measures.

ZeOmega is offering healthcare providers and organizations a free ROI assessment to determine their potential overall medical savings by deploying Jiva Integrated Medication Management. Please fill out the online form located at http://www.zeomega.com/zeomega-resources/imm-roi/ for an assessment based on your organization’s unique data.

 

About ZeOmega

ZeOmega’s powerful population health management platform delivers high-value, strategic solutions enabling payers and care-delivery organizations to improve individual health and provider performance. With deep domain expertise and a comprehensive understanding of complex population health challenges, ZeOmega serves as a “true-north” partner for clients—offering flexible deployment and delivery models that leverage an innovative platform designed to integrate workflow, analytics, content and communication capabilities. By consistently meeting customer expectations and project benchmarks, ZeOmega has earned a sterling reputation in the industry for responsiveness and reliability. For more information, visit www.zeomega.com or call 214-618-9880. Follow ZeOmega on Twitter, LinkedIn or Facebook.

 

 

# # #

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.